Application of 11C-acetate positron-emission tomography (PET) imaging in prostate cancer: systematic review and meta-analysis of the literature
- To review the literature on the application of 11C-acetate positron-emission tomography (PET) imaging in prostate cancer.
- We systematically reviewed the available literature and presented the results in meta-analysis format.
- PubMed, SCOPUS, ISI web of knowledge, Science Direct, Springer, and Google Scholar were searched with ‘Acetate AND PET AND Prostate’ as keywords.
- All studies that evaluated accuracy of 11C-acetate imaging in primary or recurrent prostate cancer were included, if enough data could be extracted for calculation of sensitivity and/or specificity.
- In all, 23 studies were included in the study. For evaluation of primary tumour, pooled sensitivity was 75.1 (69.8–79.8)% and specificity was 75.8 (72.4–78.9)%.
- For detection of recurrence, sensitivity was 64 (59–69)% and specificity was 93 (83–98)%. Sensitivity for recurrence detection was higher in post-surgical vs post-radiotherapy patients and in patients with PSA at relapse of >1 ng/mL.
- Studies using PET/computed tomography vs PET also showed higher sensitivity for detection of recurrence.
- Imaging with 11C-acetate PET can be useful in patients with prostate cancer. This is especially true for evaluation of patients at PSA relapse, although the sensitivity is overall low.
- For primary tumour evaluation (localisation of tumour in the prostate and differentiation of malignant from benign lesions), 11C-acetate is of limited value due to low sensitivity and specificity.
- Due to the poor quality of the included studies, the results should be interpreted with caution and further high-quality studies are needed.